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Abstract
The antitumorigenic potential of two palladium(II) complexes, [Pd(ca2-o-phen)Cl2] – C1 and [Pd(dmba)(dppp)Cl] –
C2, was evaluated, using MDA-MB-435 cells, a human breast adenocarcinoma cell-line that does not express the
estrogen receptor  (ER-). Growth inhibition and induced alterations in cell-morphology were analyzed. The
sulforhodamine B test showed that, compared to control cells, both C1 and C2 significantly inhibited (p < 0.5) cell
growth. The maximum effect with both was achieved with 1 M complexes, after 24 h of treatment. No further
cell-growth inhibition was achieved by increasing concentration or incubation time. Cell morphology was analyzed
after staining with hematoxylin-eosin (HE). The morphological changes noted in the treated cells were cell round-
ing-up, shrinkage, nuclear condensation and reduction of cell length (p < 0.05), thereby indicating that both C1 and
C2 are cytotoxic to breast adenocarcinoma cells. All together, there was every indication that, by decreasing cell
growth and inducing morphological changes, the tested complexes are cytotoxic, hence their potentiality as promis-
ing candidates for antineoplastic drug development.
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Introduction
Globally, 12.7 million new cases of cancer and 7.6
million deaths were estimated to have occurred in 2008.
Worldwide, the second most commonly diagnosed type is
breast cancer, with an estimated 1.4 million new cases
(10.9% of all cancers diagnosed) and 458,000 deaths in
2008 (Jemal et al., 2010). For 2010, 49,000 new cases of
breast cancer were expected for Brazil alone and 1.5 mil-
lion worldwide, with the highest mortality rates in low- and
middle-income countries (Anderson, 2010; Brazil, 2011).
Through breast carcinoma development being multi-
factorial in a multistep mutational process, cells acquire a
set of genetic lesions, leading to a cancerous state with the
subsequent forming of phenotypically different tumors.
Phenotypic changes during breast-cancer progression re-
flectaberrantgeneexpressionandpathwayssupportingde-
regulated growth. The various forms of expression of
estrogen receptor (ER), progesterone receptor, and human
epithelial growth factor receptor-2, are important molecu-
lar markers used in clinical practice for disease diagnosis,
prognosis and therapy. ER expression is one of the most
important markers for the selection of adequate breast can-
cer therapy (Giacinti et al., 2006; Oldenhuis et al., 2008;
Sahab et al., 2011). Around 60% of all breast cancers diag-
nosed are ER positive (ER+), a noninvasive differentiated
breast cancer which responds to antiestrogen therapy. Nev-
ertheless, some breast cancer cells, through losing the abil-
itytoexpressER,giverisetoatherapy-resistantcancer.ER
negative (ER-) breast cancers are a highly invasive, dedif-
ferentiated form of breast carcinoma, which have been as-
sociated with focal myoepithelial disruption, a lack of
expression of tumor suppressors, and a higher rate of cell
proliferation, itself increasing metastatic potential, thereby
posing a challenge to treatment (Sahab et al., 2011).
Despite favorable prognosis if early detected, and re-
cent progress in drug therapy, there are no effective drugs
for treating and curing most types of breast cancers, espe-
cially metastatic ER-tumors (Oldenhuis et al., 2008;
Brough et al., 2011). Serious side effects have become ob-
stacles in treatment when using current compounds with
anticanceractivity(Rybaketal.,2009),wherebytheneces-
sary search for new potential antitumor substances to im-
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Research Articleprove treatment efficacy with smaller doses and less toxic
drugs. The development of drugs that selectively eliminate
cancer cells without harming normal ones, also remains a
considerable challenge (Brough et al., 2011).
Thefirststepinthesearchfornewanticancerdrugsis
in vitro screening to detect the cytotoxic and cytostatic ef-
fectsofacompound.Collectively,cytotoxicitycomprisesa
set of biochemical and genetic alterations that disrupt cell
homeostasis, and it could be estimated by enzyme release,
cell viability, survival and death assays, among others (Su-
mantran, 2011).
Acytotoxiccompoundinducesshort-termlossofcell
viability either by triggering cell-death or decreasing cell-
survival. In contrast, a cytostatic elicits long-term cell sur-
vival or cell proliferation without affecting eventual, viable
cell-number (Sumantran, 2011). The first and most readily
observed effects, following cell exposure to toxicants, are
morphological alterations in the cell-layer and/or
cell-shape in monolayer cultures. Another indicator of
cytoxicity is altered cell growth (Ekwall et al., 1990).
Most synthetic metal complexes used as antitumor
chemotherapeutic compounds are structural analogs of
cisplatin. Recently, the palladium (II) complexes were in-
cluded among the newly introduced structural types of me-
tallic complexes, designed for increased antitumor
efficiency and decreased toxicity to normal cells (Caires et
al.,1999;Konteketal.,2011).Thefirstofthesehadlittleor
no application as antitumor compounds, due to poor stabil-
ity and rapid hydrolysis in biological environments. How-
ever, the use of chelating ligands in their synthesis was
opportune in improving their stability, which was further
improved by the generation of cyclopalladated compounds
(Caires, 2007).
Previous studies by our group have shown that the
palladium(II) complexes are cytotoxic to tumor cells (Cai-
res et al., 1999; Rocha et al., 2007), although there are no
available data on their toxicity to ER- breast tumor cells.
The aim of the present study was to evaluate the
cytotoxic activity of two synthesized palladium(II) com-
plexes in the human breast adenocarcinoma cell line,
MDA-MB-435 (ER-), a highly invasive, estrogen inde-
pendent and dedifferentiated breast carcinoma cell line, by
analyzing their effect on cell growth and morphology.
Materials and Methods
Reagents
All reagents, solvents and ligands (dmba = dimethyl-
benzylamine and dppp = (diphenylphosphine)propane)
were purchased from Sigma-Aldrich, St Louis, USA (ACS
quality) and employed without further purification.
Ligand synthesis
The iminic ligand or Schiff’s base (ca2-o-phen =
bis(cinnamaldehyde)-o-phenylenediimine) was synthe-
sized as follows: A solution of trans-cinnamaldehyde
1.14 g (8.6 mmol) in ethanol (2 mL) was added dropwise to
an ethanolic solution (20 mL) of o-phenylenediamine
0.47g(4.3mmol).Thereactionmixturewasstirredatroom
temperature for 3 h. After cooling for 24 h, a white solid
took form. The pellet was filtered off, washed with ethanol,
water and ethyl ether, and finally vacuum-dried.
Palladium(II) complex synthesis
[Pd(ca2-o-phen)Cl2] (C1)
The complex [Pd(ca2-o-phen)Cl2] (C1) was synthe-
sized as follows: A solution of imine ca2-o-phen 0.15 g
(1.16 mmol) in methanol (20 mL) was slowly added
dropwise to a solution containing palladium(II) chloride
0.411 g (2.32 mmol) and lithium chloride 0.197 g
(4.46 mmol) dissolved in methanol (50 mL). The resulting
solution was stirred at room temperature for 8 h. The pale
yellow pellet thus formed was filtered off and washed with
ethanol, water and ethyl ether, and then vacuum-dried.
[Pd(dmba)(dppp)Cl] (C2)
Synthesis of [Pd(dmba)(dppp)Cl] (C2) has already
been described (Caires et al., 1999). Planar molecular ge-
ometry of the two palladium(II) complexes synthesized is
shown in Figure 1. Both were dissolved in DMSO
(1 mg.mL
-1) and diluted with distilled water to obtain the
desired concentration.
Cell line culture
Human breast adenocarcinoma MDA-MB-435 cells
were purchased from the Rio de Janeiro Cell Bank (CR
117), and cultured in RPMI 1640, supplemented with 20%
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Figure 1 - Structures of palladium(II) complexes. C1, [Pd(ca2-o-
phen)Cl2]; C2, [Pd(dmba)(dppp)Cl].(v/v) inactivated fetal bovine serum, 100 U.mL
-1 penicillin
and 100 g.mL
-1 streptomycin. Cells were maintained in a
humidified atmosphere with 5% CO2 at 37 °C. Before be-
ginning each experiment, cell viability was assessed by the
trypan blue-dye exclusion method and 2.10
4 viable
cells.mL
-1 were used in all experiments.
Cell growth analysis
The effect of C1 and C2 complexes on cell growth
was determined by the sulforhodamine B (SRB) colori-
metric assay (Vichai and Kirtikara, 2006). Briefly, cells
were seeded onto 96-well plates, and then left for 24 h to
reach exponential growth. The medium was replaced,
whereupon the cells were treated with vehicle (negative
control), 5.0 M cisplatin (positive control), or various
concentrations of both complexes (0.1, 0.5, 1.0, 5.0 and
10.0 M). Cells were then incubated for 24 and 48 h and
fixed with 10% trichloroacetic acid (w/v) for 30 min at
4 °C. After careful removal of the plate content, each well
was washed with distilled water. The plate was then dried
for 24 h and stained with 0.4% SRB (w/v) in 1% acetic acid
(v/v) for 30 min, after which, excess SRB was removed,
andthewellswashed4timeswith1%aceticacid(v/v).The
bound SRB was dissolved by adding 100 Lo f1 0M Tris
pH 10.5 for 10 min and absorbance read at 510 nm.
Morphological analysis
Morphological analysis, with modifications, was as
describedbyPedroetal.(2006).Inordertoreachexponen-
tial growth, cells were cultured on coverslips for 24 h to
achieve the exponential growth, whereupon the medium
was replaced, and the cells treated with various concentra-
tionsoftheC1andC2complexes(0.1,0.5,1.0and5.0M)
for 24 h. Cells treated with the vehicle were the negative
control, and with 5.0 M cisplatin, the positive. After treat-
ment, cells were fixed with 70% acetone and stained with
hematoxylin-eosin. Slides were mounted in Entellan and
observed by light microscopy. Cell digital images were ac-
quired with an Olympus BX52 microscope and Motic Im-
ages Plus 2.0 software. Fifteen aleatory fields were
analyzed per treatment, to describe cell morphology. In
each treatment, 30 cells (two per field) were measured with
Motic Images Plus 2.0 software, in order to determine cell
length.
Statistical analysis
Obtained data were compared by one-way analysis of
variance (ANOVA), followed by the Tukey test, when
p < 0.05. Data are shown as the mean  SEM of three inde-
pendent experiments.
Results and Discussion
After completing synthesis, the palladium(II) com-
plexes were investigated for in vitro antitumor activity
when using the hormone-insensitive human breast-cancer
cell line, MDA-MB-435. This cell-line does not express
ER, and has been used as the model in metastatic breast-
cancer studies. Even though some previously synthesized
palladium(II) complexes have proved to be cytotoxic to tu-
mor cells, their effect on breast-cancer cells remains un-
known. It is also important to evaluate the cytotoxicity of
newly synthesized complexes with increased stability, the
case of C1.
We evaluated the cytotoxicity of C1 and C2 com-
plexes using the SRB assay (Figure 2). SRB, in moderated
acid conditions, binds stoichiometrically to basic protein
aminoacids. The OD observed is well correlated to cell
number, thus being an indicator of the cell growth (Vichai
and Kirtikara, 2006). The results depicted in Figure 2 show
that both complexes hindered cell growth and the maxi-
mum effect was obtained with 1 M C1 and C2 after 24 h
incubation. No further significant (p > 0.05) hinderance
was achieved by increasing C1 and C2 concentration or in-
cubation time. Thus, it is possible to sustain the positive
cytotoxic role of these synthesized complexes in the inhibi-
tion of MDA-MB-435 cell growth and spread.
C1, C2 and cisplatin treatment induced alterations in
cell morphology, such as nuclear condensation, cell round-
ing-up and shrinkage indicating cytoskeleton disruption
(Figure 3). Untreated control cells presented irregular spin-
dle-shaped morphology, were homogeneously stained,
withthecytoplasmlessstainedthanthenucleusandthenu-
cleolus remained plainly visible. On the other hand, when
exposed to C1 and C2 complexes, cells became rounded
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Figure 2 - Cell growth inhibition (%) after treatment with different palla-
dium(II) complex (C1 and C2) concentrations for 24 and 48 h, estimated
by the sulforhodamine B assay. C1, [Pd(ca2-o-phen)Cl2]; C2,
[Pd(dmba)(dppp)Cl].Growthinhibitionwascalculatedrelativetotheneg-
ative control. The results are expressed as mean  SEM of three independ-
ent experiments. Note that the results were similar in both cases.and individually separated, with cell shrinkage, nuclear
condensation and wrinkled cytoplasmic membranes.
When undergoing C1 and C2 treatment for 24 and
48 h, there was a significant (p < 0.01) decrease in cell-
length in comparison to control cells. The complex effect
proving to be similar to the cisplatin (Figure 4), even at
lower concentrations. All told, these morphological alter-
ations indicated C1 and C2 cytotoxicity.
TheresultshereincorroboratethefindingsofBarbosa
etal.(2006)showingpalladium(II)complexcytotoxicityto
cultured cells, with a decrease in cell number, chromatin
condensation, and consequent viability reduction.
Caires et al. (1999), when studying C6, HeLa and
Hep-2 cell lines, observed cell-growth inhibition upon pal-
ladium(II) complex treatment, with concentrations higher
than those obtained in the present work. Here, the maxi-
mum effect on cell-growth inhibition was achieved with
0.1 M C1 and C2 complex treatments.
It has been demonstrated that palladium (II) com-
plexes can bind to DNA in both the coordination and
intercalative modes, thereby forming the DNA adducts in-
volved in cytotoxic specificity and significant cancer-cell
inhibitory activities (Gao et al. 2010, 2011). In the present
work, the cytotoxic effect of palladium(II) complexes, pos-
siblyduetocomplex-DNAinteraction,wasclearlyshown.
In conclusion, the tested C1 and C2 palladium(II)
complexes showed growth inhibition activity and induced
alterationsincellmorphology,bothcompatiblewithcyto-
toxicity against human breast adenocarcinoma
MDA-MB-435 cells. The cytotoxic effect is an indicative
ofthecompoundantitumoractivityasthemajorityofclin-
ical used antitumor drugs show cytotoxic activity (Le
Tourneau et al., 2010). This is the first report on the C1
and C2 complexes activity against breast cancer cells and
they seem to be good candidates for antineoplastic drug
development.
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Figure 4 - MDA-MB-435 cell length (m) after 24 h incubation. Cont,
controlcells;Cisp,cellstreatedwith5Mcisplatin;C1,cellstreatedwith
[Pd(ca2-o-phen)Cl2]; C2, cells treated with [Pd(dmba)(dppp)Cl]. Note
cell-length reduction after treatment, in comparison to control cells,
thereby indicating Pd(II) complex cytotoxicity. Results are expressed as
mean  SEM of three independent experiments. Different letters indicate
significant differences (p < 0.01) by the Tukey test.
Figure 3 - Morphology of MDA-MB-435 cells stained with hematoxylin
and eosin, after 24 h incubation. Cont, control cells; Cisp, cells treated
with 5 M cisplatin; C1, cells treated with [Pd(ca2-o-phen)Cl2]; C2, cells
treated with [Pd(dmba)(dppp)Cl]. Palladium(II) complexes were added to
the cell culture at 0.1, 0.5, 1.0 and 5.0 M. All the pictures are typical of
three independent experiments, each carried out under identical condi-
tions. Bar = 20 m. N – nucleolus; R – rounding; NC – nuclear condensa-
tion; W – wrinkled cytoplasmic membranes.Acknowledgments
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